RFA
CLDI icon

Reyes Financial Architecture’s Calidi Biotherapeutics CLDI Stock Holding History

Reyes Financial Architecture’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17 Hold
100
– – ﹤0.01% 317
2026
Q1 		$24 Hold
100
– – ﹤0.01% 347
2025
Q4 		$117 Hold
100
– – ﹤0.01% 384
2025
Q3 		$152 Buy
+100
New +$425 ﹤0.01% 299

Other funds holding CLDI

RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Reyes Financial Architecture's CLDI Position: Q2 2026 in Review

Reyes Financial Architecture held its Calidi Biotherapeutics (CLDI) position steady in Q2 2026 at 100 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #317.

Reyes Financial Architecture first reported a position in CLDI in Q3 2025 and has held it in 4 quarters since. The position peaked at $152 in Q3 2025. 3 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Reyes Financial Architecture held 100 shares of Calidi Biotherapeutics worth $17 as of Q2 2026.
  • Reyes Financial Architecture left its Calidi Biotherapeutics share count unchanged in Q2 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of Reyes Financial Architecture's portfolio in Q2 2026, its #317 holding.
  • Reyes Financial Architecture first reported a position in Calidi Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • Reyes Financial Architecture's Calidi Biotherapeutics position peaked at $152 in Q3 2025.
  • 3 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Reyes Financial Architecture's 13F filing for Q2 2026, filed 17 Jul 2026.